TY - JOUR
T1 - Behandeling van infantiele hemangiomen met propranolol
T2 - Goede resultaten en weinig bijwerkingen
AU - Hermans, Denise J.J.
AU - Ottenhof, Maarten J.
AU - Wijnen, Marc H.W.A.
AU - Van Beynum, Ingrid M.
AU - Van Der Horst, Chantal M.A.M.
AU - Van Der Vleuten, Carine J.M.
PY - 2011/10/8
Y1 - 2011/10/8
N2 - Infantile haemangiomas (IH) are the most commonly occurring benign tumours of infancy, which may lead to considerable morbidity, such as amblyopia, ulceration and airway obstruction, depending on localization. Until recently, treatment was difficult: high-dose systemic glucocorticoids had limited effect and serious side effects. In 2008, the effectiveness of the beta-blocker propranolol for infantile haemangiomas was discovered; by now there is extensive worldwide experience. Data from the literature and from our own patient cohort (n = 132) confirm the remarkable efficacy of propranolol in complicated IH, without significant adverse effects. Propranolol is most effective in the proliferation phase of IH in children under 6 months of age. Timely referral of patients with potentially function-threatening or life-changing IH to a specialised multidisciplinary centre is therefore essential. Pending controlled studies, propranolol appears to have become the first choice treatment in complicated IH.
AB - Infantile haemangiomas (IH) are the most commonly occurring benign tumours of infancy, which may lead to considerable morbidity, such as amblyopia, ulceration and airway obstruction, depending on localization. Until recently, treatment was difficult: high-dose systemic glucocorticoids had limited effect and serious side effects. In 2008, the effectiveness of the beta-blocker propranolol for infantile haemangiomas was discovered; by now there is extensive worldwide experience. Data from the literature and from our own patient cohort (n = 132) confirm the remarkable efficacy of propranolol in complicated IH, without significant adverse effects. Propranolol is most effective in the proliferation phase of IH in children under 6 months of age. Timely referral of patients with potentially function-threatening or life-changing IH to a specialised multidisciplinary centre is therefore essential. Pending controlled studies, propranolol appears to have become the first choice treatment in complicated IH.
KW - Adrenergic beta-Antagonists/adverse effects
KW - Child
KW - Child, Preschool
KW - Disease Progression
KW - Hemangioma/drug therapy
KW - Humans
KW - Infant
KW - Infant, Newborn
KW - Propranolol/adverse effects
KW - Treatment Outcome
UR - http://www.scopus.com/inward/record.url?scp=80054821087&partnerID=8YFLogxK
M3 - Artikel
C2 - 21988755
SN - 0028-2162
VL - 155
SP - 1793
EP - 1802
JO - Nederlands tijdschrift voor geneeskunde
JF - Nederlands tijdschrift voor geneeskunde
IS - 40
ER -